My Cart [ 0 ]
Home > Antibodies > Research-Grade Biosimilars > Cofetuzumab Biosimilar, PTK7 Monoclonal Antibody

Cofetuzumab Biosimilar, PTK7 Monoclonal Antibody

Protein Tyrosine Kinase 7

Catalog No. Product Name Size List Price (US$) Quantity
C107P Cofetuzumab Biosimilar, Human PTK7 Monoclonal Antibody 1 mg 175.00
C107P Cofetuzumab Biosimilar, Human PTK7 Monoclonal Antibody 5 mg 600.00
C107P Cofetuzumab Biosimilar, Human PTK7 Monoclonal Antibody 20 mg 1200.00
C107P.NA Cofetuzumab Biosimilar, N297A Mutant 0.5 mg 375.00
C107P.LA Cofetuzumab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant 0.5 mg 375.00
Description

C107P: Cofetuzumab Biosimilar, PTK7 Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype: Human IgG1 kappa.
Source: The anti-human Protein Tyrosine Kinase 7 (PTK7) monoclonal antibody cofetuzumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade cofetuzumab biosimilar specifically binds to the PTK7 protein.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by cofetuzumab.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The research grade cofetuzumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

What is cofetuzumab biosimilar research grade? Cofetuzumab is a humanized IgG1-kappa monoclonal antibody against PTK7, which is a tumor-associated antigen (TAA) and overexpressed on a variety of cancer cells. Cofetuzumab pelidotin is an antibody-drug conjugate (ADC) composed of cofetuzumab linked, via a cleavable valine-citrulline linker, to an analog of the auristatin microtubule inhibitor dolastatin 10, auristatin-0101, with potential antineoplastic activity. Upon administration, cofetuzumab pelidotin targets and binds to PTK7 expressed on tumor cells. Upon binding, internalization and cleavage, auristatin-0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of PTK7-expressing tumor cells.  Cofetuzumab biosimilar uses the same protein sequences as the therapeutic antibody cofetuzumab.

Syd Labs provides the following research grade antibody biosimilars used in ADCs:
Tusamitamab biosimilar, research grade, anti-human CEACAM5 monoclonal antibody
Rovalpituzumab biosimilar, research grade, anti-human DLL3 monoclonal antibody
Trastuzumab biosimilar, research grade, anti-human HER2 monoclonal antibody
Cofetuzumab biosimilar, research grade, anti-human PTK7 monoclonal antibody
Ifinatamab biosimilar, research grade, anti-human B7-H3 (CD276) monoclonal antibody
Sacituzumab biosimilar, research grade, anti-human Trop-2 monoclonal antibody
Gemtuzumab biosimilar, research grade, anti-human CD33 monoclonal antibody
Polatuzumab biosimilar, research grade, anti-human CD79B monoclonal antibody
Cetuximab biosimilar, research grade, anti-human EGFR monoclonal antibody

Related Links

See our Privacy Policy